PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage biotechnology company focused on developing precision oncology therapies targeting p53 mutations. The core business activity in cancer treatment development is Shariah-compliant, aligning with Islamic principles of preserving life. However, financial screening reveals non-compliance primarily due to an excessively high liquidity ratio (244.3%) exceeding thresholds across AAOIFI, MSCI, and S&P standards, indicating potential riba exposure in cash management. No non-permissible income or significant debt issues are present. Overall, while business activities are permissible, the stock is classified as NON_COMPLIANT based on index exclusions and quantitative failures.